Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | STAT3 | P40763 | 4/20 | 0.62 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23974724 | 0.98 | CRBN (0.66) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL29400212 | 0.98 | CRBN (0.66) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL19451305 | 0.98 | CRBN (0.66) | CRBNDDB1CA2STAT3DYRK2 | |
| Hydrochloric Acid SCHEMBL31146577 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL21815163 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL21106333 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL19451344 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL23702572 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL19451340 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 | |
| SCHEMBL30834691 | 0.97 | CRBN (0.65) | CRBNDDB1CA2STAT3DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 1386/4885DDB1 328/4885CA2 4649/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CRBN 183/4885DDB1 3837/4885CA2 4280/4885 |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885CA2 4536/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885CA2 4536/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | CRBN 1386/4885DDB1 328/4885CA2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.